Cao Ke-jian, Gao Cheng-xin, Qin Yuan, Hu Ding-zhong, Shi Jian-xin, Yang Jun
Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China.
Zhonghua Wai Ke Za Zhi. 2007 Jun 15;45(12):818-21.
To summarize the diagnosis and treatment of acute rejection after lung transplantation and to discuss optimized immunosuppressive therapy.
Between November 2002 and June 2006, 16 patients underwent operations on lung transplantation, 7 cases on single-lung transplantation and 9 cases on bilateral-lung transplantation. Immunosuppressive therapy was new triple drug maintenance regimen including tacrolimus (Tac), mycophenolate mofetil (MMF) and steroids, and (or) daclizumab.
Eight cases in new triple drug maintenance regimen with daclizumab. There is no acute rejection in 6 months. Except 2 of the 8 cases died of early post-lung transplantation sever pulmonary edema and dysfunction, 3 of the rest 6 cases underwent acute rejection incident about 21.4% (3/14).
In this group the new triple drug maintenance regimen including tacrolimus (Tac), mycophenolate mofetil (MMF) and steroids, and (or) daclizumab acquired beneficial effect in preventing acute rejection after lung transplantation.
总结肺移植术后急性排斥反应的诊断与治疗，并探讨优化的免疫抑制治疗方案。
2002年11月至2006年6月，16例患者接受了肺移植手术，其中单肺移植7例，双肺移植9例。免疫抑制治疗采用新的三联药物维持方案，包括他克莫司（Tac）、霉酚酸酯（MMF）和类固醇，以及（或）达利珠单抗。
8例采用含达利珠单抗的新三联药物维持方案。6个月内无急性排斥反应发生。8例中除2例死于肺移植术后早期严重肺水肿和功能障碍外，其余6例中有3例发生急性排斥反应事件，发生率约为21.4%（3/14）。
在该组患者中，包括他克莫司（Tac）、霉酚酸酯（MMF）和类固醇以及（或）达利珠单抗的新三联药物维持方案在预防肺移植术后急性排斥反应方面取得了有益效果。
